Since roughly 70% of DMD patients have a single-exon or multi-exon deletion or duplication in the dystrophin gene, multiplex ligation-dependent probe amplification (MLPA) or comparative genomic hybridization array are typically performed as the initial confirming test. This evidence concerns the gene DMD and Duchenne muscular dystrophy.